menu search

Akero therapeutics inc stock tanks after nash liver treatment study disappoints

Akero Therapeutics Inc shares lost roughly two-thirds of their value Tuesday morning after the company released a disappointing update on its fatty li...

October 10, 2023, 11:51 am

Akero therapeutics shares plunge on liver disease treatment's mixed results

Akero Therapeutics Inc. shares AKRO, -3.56% fell more than 60% premarket on Tuesday after the company released an update on its lead product candidate...

October 10, 2023, 8:10 am

Sagimet biosciences: recent ipo with emerging positive data in nash

Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows pro...

September 27, 2023, 2:48 pm

Madrigal pharmaceuticals reports inducement grants under nasdaq listing rule 5635(c)(4)

CONSHOHOCKEN, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursui...

September 14, 2023, 8:30 pm

Madrigal (mdgl) gains on nda for nash therapy acceptance by fda

Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets...

September 14, 2023, 9:01 am

Terns pharmaceuticals: facing impressive competition, but not completely out of its depth

TERN's TERN-701 is being developed for Chronic Myeloid Leukemia (CML), but NVS' Scemblix is similar and already approved. TERN-701 may offer benefits ...

July 20, 2023, 1:11 pm

Madrigal pharmaceuticals completes submission of new drug application seeking accelerated approval of resmetirom for the treatment of nash with liver fibrosis

CONSHOHOCKEN, Pa., July 17, 2023 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuin...

July 15, 2023, 6:59 am

What earnings will be released next week?

The earnings calendar was unofficially started today with the release of some of the major banks including J.P. Morgan, Citigroup, and Wells Fargo. So...

July 14, 2023, 5:51 pm

Sagimet biosciences sets ipo terms, to raise up to about $80 million

Sagimet Biosciences Inc. SGMT, disclosed Monday terms for its initial public offering, in which the California-based biopharmaceutical company focused...

July 10, 2023, 7:05 am

: madrigal pharmaceuticals’ stock up 5% as company starts rolling submission for fda approval of nash treatment

Madrigal Pharmaceuticals Inc.’s stock MDGL rose 5% Friday after the company said it has started a rolling submission of a New Drug Application to th...

June 30, 2023, 4:28 pm

Madrigal pharmaceuticals' stock up 5% as company starts rolling submission for fda approval of nash treatment

Madrigal Pharmaceuticals Inc.'s stock MDGL, +5.00% rose 5% Friday after the company said it has started a rolling submission of a New Drug Application...

June 30, 2023, 12:28 pm

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Intercept (icpt) nda for nash treatment gets crl from fda

Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to no...

June 23, 2023, 1:24 pm

Akero says nash drug shown to reduce liver fat by 65% in some patients

Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a ...

June 5, 2023, 11:02 am

Madrigal pharmaceuticals announces participation at two upcoming investor conferences

CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursui...

June 1, 2023, 12:00 pm


Search within

Pages Search Results: